+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • PDF Icon

    Report

  • 71 Pages
  • April 2022
  • Region: Global
  • Global Markets Direct
  • ID: 5589929
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

According to the recently published report 'Leucine Rich Repeat Serine Threonine Protein Kinase 2 - Drugs In Development, 2022'; Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) pipeline Target constitutes close to 25 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes.

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Leucine-rich repeat kinase 2 (LRRK2) is an enzyme encoded by the PARK8 gene. It plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose 6 phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner together with RAB29. It regulates neuronal process morphology in the intact central nervous system.

The report 'Leucine Rich Repeat Serine Threonine Protein Kinase 2 - Drugs In Development, 2022' outlays comprehensive information on the Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 13 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Report covers products from therapy areas Central Nervous System, Cardiovascular, Gastrointestinal, Oncology and Ophthalmology which include indications Parkinson's Disease, Amyotrophic Lateral Sclerosis, Crohn's Disease (Regional Enteritis), Glioblastoma Multiforme (GBM), Ocular Hypertension, Open-Angle Glaucoma, Pancreatic Cancer, Pulmonary Hypertension, Triple-Negative Breast Cancer (TNBC) and Unspecified Neurologic Disorders.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The report provides a snapshot of the global therapeutic landscape for Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1)
  • The report reviews Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics

Reasons to Buy


  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

IntroductionReport CoverageLeucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Overview
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
  • 1st Bio Therapeutics Inc
  • Arrien Pharmaceuticals LLC
  • Blue Therapeutics Inc
  • Cerevel Therapeutics Holdings Inc
  • D. Western Therapeutics Institute Inc
  • Denali Therapeutics Inc
  • E-scape Bio Inc
  • Guangzhou DM Intelligence Ltd
  • H. Lundbeck AS
  • Halia Therapeutics Inc
  • ICB International Inc
  • Imago Pharmaceuticals Inc
  • Ionis Pharmaceuticals Inc
  • Lead Discovery Center GmbH
  • Merck & Co Inc
  • Neuron23 Inc
  • Oncodesign SA
  • Shape Therapeutics Inc
  • Voronoi Group
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Drug Profiles
  • Antibody 1 to Inhibit LRRK2 for Parkinson's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Antibody to Inhibit LRRK2 for Parkinson's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • ARN-1104 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • DNL-151 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • DNL-201 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • DNL-975 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Drug to Inhibit LRRK2 for Parkinson's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Drug to Inhibit LRRK2 for Unspecified Neurologic Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • ESB-5070 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • FB-418 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • GNE-7915 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • H-1337 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • ION-859 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • NEU-723 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • ODS-2005294 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • PF-06447475 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • SHP-202 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Small Molecule to Inhibit LRRK-2 for Parkinson's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Small Molecule to Inhibit LRRK2 for Parkinson's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Small Molecules to Inhibit LRRK-2 for Parkinson's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • VRN-01 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Dormant ProductsLeucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
  • Jun 14, 2021: Servier and Oncodesign announce the selection of a preclinical candidate as part of their collaboration targeting new treatments for Parkinson’s Disease
  • May 01, 2021: Phase 1b studies of its LRRK2 inhibitor, BIIB122/DNL151, supporting late-stage development plans in Parkinson’s Disease
  • Aug 06, 2020: Biogen and Denali to collaborate on LRRK2 program for Parkinson’s Disease and certain tv platform-enabled programs for neurodegenerative diseases
  • Aug 06, 2020: Denali Therapeutics announces decision to advance DNL151 into late stage clinical studies in Parkinson’s Patients
  • Feb 17, 2020: Oncodesign and Servier reach a key first milestone in their strategic partnership on LRRK2 inhibitors for Parkinson’s Disease
  • Sep 05, 2019: Denali begins dosing Parkinson’s patients in Phase Ib trial
  • Sep 04, 2019: GeoVax announces publication of Lassa Fever Vaccine study results
  • Sep 04, 2019: BioXcel Therapeutics receives FDA Orphan Drug Designation for BXCL701 for the treatment of Acute Myeloid Leukemia (AML)
  • Dec 10, 2018: Denali Therapeutics announces first patient dosed in phase 1b study of DNL201 for parkinson's disease
  • Aug 01, 2018: Denali Therapeutics announces positive clinical results from LRRK2 inhibitor program for parkinsons disease
  • Apr 05, 2018: Allysta Pharmaceuticals Doses First Patient in Phase 2A Study in Glaucoma
  • Dec 20, 2017: Denali Therapeutics Provides Update on DNL151
  • Dec 20, 2017: Denali Therapeutics Announces Advancement and Expansion of Its LRRK2 Inhibitor Clinical Program for Parkinson's Disease
  • May 23, 2017: Origenis Announces Patent Grants for Lead Small Molecule LRRK2 Inhibitors for Treatment of Neurodegenerative and Inflammatory Diseases
  • May 30, 2016: Oncodesign is granted new patent protecting key molecules generated from its Nanocyclix technology platform for next generation kinase inhibitors
AppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact the Analyst
List of Tables
  • Number of Products under Development by Stage of Development, 2022
  • Number of Products under Development by Therapy Areas, 2022
  • Number of Products under Development by Indication, 2022
  • Number of Products under Development by Companies, 2022
  • Products under Development by Companies, 2022
  • Number of Products under Investigation by Universities/Institutes, 2022
  • Products under Investigation by Universities/Institutes, 2022
  • Number of Products by Stage and Mechanism of Actions, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
  • Pipeline by 1st Bio Therapeutics Inc, 2022
  • Pipeline by Arrien Pharmaceuticals LLC, 2022
  • Pipeline by Blue Therapeutics Inc, 2022
  • Pipeline by Cerevel Therapeutics Holdings Inc, 2022
  • Pipeline by D. Western Therapeutics Institute Inc, 2022
  • Pipeline by Denali Therapeutics Inc, 2022
  • Pipeline by E-scape Bio Inc, 2022
  • Pipeline by Guangzhou DM Intelligence Ltd, 2022
  • Pipeline by H. Lundbeck AS, 2022
  • Pipeline by Halia Therapeutics Inc, 2022
  • Pipeline by ICB International Inc, 2022
  • Pipeline by Imago Pharmaceuticals Inc, 2022
  • Pipeline by Ionis Pharmaceuticals Inc, 2022
  • Pipeline by Lead Discovery Center GmbH, 2022
  • Pipeline by Merck & Co Inc, 2022
  • Pipeline by Neuron23 Inc, 2022
  • Pipeline by Oncodesign SA, 2022
  • Pipeline by Shape Therapeutics Inc, 2022
  • Pipeline by Voronoi Group, 2022
  • Dormant Projects, 2022

List of Figures
  • Number of Products under Development by Stage of Development, 2022
  • Number of Products under Development by Therapy Areas, 2022
  • Number of Products under Development by Top 10 Indications, 2022
  • Number of Products by Stage and Mechanism of Actions, 2022
  • Number of Products by Routes of Administration, 2022
  • Number of Products by Stage and Routes of Administration, 2022
  • Number of Products by Molecule Types, 2022
  • Number of Products by Stage and Top 10 Molecule Types, 2022

Companies Mentioned

A selection of companies mentioned in this report includes:

  • 1st Bio Therapeutics Inc
  • Arrien Pharmaceuticals LLC
  • Blue Therapeutics Inc
  • Cerevel Therapeutics Holdings Inc
  • D. Western Therapeutics Institute Inc
  • Denali Therapeutics Inc
  • E-scape Bio Inc
  • Guangzhou DM Intelligence Ltd
  • H. Lundbeck AS
  • Halia Therapeutics Inc
  • ICB International Inc
  • Imago Pharmaceuticals Inc
  • Ionis Pharmaceuticals Inc
  • Lead Discovery Center GmbH
  • Merck & Co Inc
  • Neuron23 Inc
  • Oncodesign SA
  • Shape Therapeutics Inc
  • Voronoi Group